SBC Medical Group (NASDAQ:SBC) Stock Rating Upgraded by Wall Street Zen

SBC Medical Group (NASDAQ:SBC) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other analysts also recently commented on SBC. Weiss Ratings downgraded shares of SBC Medical Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 22nd. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of SBC Medical Group in a report on Thursday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.50.

SBC Medical Group Stock Performance

Shares of SBC opened at $3.66 on Friday. SBC Medical Group has a 52-week low of $2.78 and a 52-week high of $5.07. The company has a quick ratio of 3.27, a current ratio of 3.31 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $3.08 and its two-hundred day moving average is $3.56. The stock has a market cap of $375.44 million, a PE ratio of 7.79 and a beta of 0.59.

SBC Medical Group (NASDAQ:SBC) last issued its earnings results on Thursday, August 13th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). The business had revenue of $49.19 million during the quarter, compared to analyst estimates of $45.37 million. SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%. Research analysts forecast that SBC Medical Group will post 0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SBC. Bank of New York Mellon Corp purchased a new stake in shares of SBC Medical Group in the second quarter valued at about $83,000. Russell Investments Group Ltd. raised its stake in SBC Medical Group by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock worth $51,000 after purchasing an additional 8,771 shares during the period. Barclays PLC raised its stake in SBC Medical Group by 123.7% during the fourth quarter. Barclays PLC now owns 17,779 shares of the company’s stock worth $77,000 after purchasing an additional 9,831 shares during the period. Wells Fargo & Company MN raised its stake in SBC Medical Group by 195.1% during the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock worth $54,000 after purchasing an additional 8,348 shares during the period. Finally, Nuveen LLC acquired a new position in SBC Medical Group in the 4th quarter valued at about $53,000. Institutional investors and hedge funds own 60.82% of the company’s stock.

Key Headlines Impacting SBC Medical Group

Here are the key news stories impacting SBC Medical Group this week:

• Positive Sentiment: Strong second-quarter growth: SBC reported revenue of $49.19 million, up 13% year over year and ahead of the $45.37 million analyst estimate. Net income jumped 335%, while adjusted EBITDA increased 32%, indicating improved profitability following the company’s restructuring. SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Ambitious clinic expansion: Management outlined a goal of reaching 1,000 clinics by 2035 and identified as much as $15 million in potential annual fee revenue. The targets support the company’s long-term growth narrative and could improve recurring revenue if executed successfully. SBC targets 1,000 clinics by 2035 while outlining $15M annual fee upside
• Positive Sentiment: Analyst confidence: BTIG Research reaffirmed its “buy” rating and set an $8.00 price target, implying substantial upside from the recent trading level. BTIG Research rating information
• Neutral Sentiment: Key earnings caveat: Quarterly EPS was $0.10, below the $0.12 consensus estimate. However, the revenue beat and sharp increases in net income and EBITDA may be receiving greater attention from investors.
• Negative Sentiment: Execution risk remains: The 1,000-clinic objective extends through 2035, so achieving the projected fee opportunity will depend on sustained expansion, successful integration and continued profitability improvements. SBC Q2 2026 earnings call transcript

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.